MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine

BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Seferoğlu, Meral, Ethemoğlu, Özlem, Turan, Ömer Faruk, Siva, Aksel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223191/
https://www.ncbi.nlm.nih.gov/pubmed/34165650
http://dx.doi.org/10.1007/s10072-021-05409-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223191/
https://www.ncbi.nlm.nih.gov/pubmed/34165650
http://dx.doi.org/10.1007/s10072-021-05409-6

Ejemplares similares